Piper Jaffray Downgrades ACADIA Pharma (ACAD) to Neutral
More News related to ACAD
- ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008
- Acadia Pharmaceuticals (ACAD) Reports Q3 Loss of $0.42, Beats by 3c
- ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results
- ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
- ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008
More News related to Downgrades
- After-Hours Movers 12/05: Actuate (ACTU) Up On Higher Tender Offer, RF Micro (RFMD) Lower on Guidance
- Trading Radar for 12/05: Big Lots (BIG), Flow Int'l (FLOW), Blyth (BTH) Report; Nonfarm Payrolls, Unemployment Rate, Consumer Credit Due
- Unusual 11 Mid-Day Movers 12/04: DXCM, TLB, PRKR, PSS Higher; CRUS, DMND, ITWO, DDMX Lower
- Notable Analyst Rating Changes 12/04: AMZN, YRCW, GPN, TRI Upgraded; DMND, DOX, FMCN, ISIL Downgraded
- Morning Movers 12/04: Merck (MRK) Lower On Guidance, Amazon.com (AMZN) Higher On Upgrade
Piper Jaffray downgrades ACADIA Pharmaceuticals (Nasdaq: ACAD) from Buy to Neutral and lowers its price target from $6 to $3.
The firm believes ACADIA's announcement that it would be cutting its workforce in half, in addition to the announced $60 million in committed equity financing, has taken its potential partnership for pimavanserin "off the table." This assumption implies that studies of pimavanserin on other diseases, such as schizophrenia, will also be delayed.
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Related Categories
DowngradesStocks Mentioned
+0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
